Johnson & Johnson
Search results
4 days ago · See also Study shows first dose of Pfizer vaccine 85 per cent effective after 2-4 weeks. This protection persisted, with an efficacy rate of 69.4% at 180 days and 41.0% at one year.
4 days ago · Pfizer Singapore announced that the Health Sciences Authority has approved the company’s Abryvso vaccine for respiratory syncytial virus (RSV). This vaccine aims to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age and for individuals 60 years of age and older.
4 days ago · Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...
3 days ago · (Bloomberg) -- European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking it.Most ...
4 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
2 days ago · 52 Week High Date 10/03/23. 52 Week Low 25.20. 52 Week Low Date 04/26/24. Market Cap 164.844B. Shares Out 5.67B. 10 Day Average Volume 28.92M. Dividend 1.68. Dividend Yield 5.78%. Beta 0.65.
2 days ago · Annalee Armstrong is senior editor at BioSpace. Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
